CLINICAL SUPPLY REGULATORY ARTICLES
Have We Got Novel Drug Production And Compliance Timelines All Wrong?
Drug developers might want to consider longer-term approaches to meeting manufacturing and regulatory requirements.
CLINICAL SUPPLY REGULATORY RESOURCES
-
One of the most significant changes in the new EU regulation is Annex VI, which covers changes in the labelling requirements for investigational medical products (IMPs). So, what are the implications of these changes and how will they affect outer immediate packaging?
-
Learn how by having a strategy for “core-to-carton” compliance, drug developers can avoid risks for patients and their company.
-
Perhaps more than any other industry, pharma and biotech have undergone radical change over the past year, as a result of the COVID-19 pandemic. From supply chain security and capacity to clinical trial operations and site auditing, almost every aspect has been affected. Experts explore how these trends are shaping the industry and offer an outlook.
-
Preparing for a regulatory inspection during a clinical trial can be daunting. Learn about the importance of clear roles, audit trails, data integrity, and training, and get recommendations to help.
-
Discover top challenges that emerging biologics face, packaging containment offerings and services that help mitigate risks, and ways to reduce obstacles that slow development.
-
Learn how a top 20 US-based pharma company achieved more capacity to meet commercial supply needs in an accelerated timeline followed by pre-approval inspection with the help of a CMO partner.
-
CMC is evolving with digitalization, sustainability, supply chain resilience, post-merger integration, and personalized medicine.